Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. rivelin-clo

RIVELIN-CLO SIGNED

The Ultimate Therapy for the Oral Lichen Planus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RIVELIN-CLO project word cloud

Explore the words cloud of the RIVELIN-CLO project. It provides you a very rough idea of what is the project "RIVELIN-CLO" about.

7    mucosal    84m    alleviation    painful    undesired    occlusion    ongoing    perspectives    cure    dosing    international    spread    ultimately    ip    employees    erosive    kept    rivelin    approved    self    therapeutic    saliva    therapeutics    disorder    diseases    adherence    oral    guarantee    danish    correct    goals    chance    efficacy    damage    gather    clinical    treat    sensations    reg    chronic    revenues    ways    combined    company    afyx    planus    generating    treatment    founded    time    iib    minimization    launch    generate    involve    clobetasol    lesions    patch    primary    causing    10m    2014    commercial    venture    market    hospitals    lives    olp    2h    struggle    tissues    topical    trials    suffering    drug    burning    mucosa    lichen    daily    exclusively    symptoms    normal    options    clo    usa    lesion    electrospinning    launching    immune    corticosteroids    prevented    innovative    clinics    markets    first    financial    lower    22    people    potentially    systemic    living    worldwide    share    lack    bystander    6m    precancerous    toxicity    patients    staff    incorporating   

Project "RIVELIN-CLO" data sheet

The following table provides information about the project.

Coordinator		 AFYX THERAPEUTICS A/S 

Organization address
address: LERGRAVSVEJ 57, 2TV.
city: COPENHAGEN
postcode: 2300
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AFYX THERAPEUTICS A/S DK (COPENHAGEN) coordinator 50˙000.00

Map

 Project objective

Oral lichen planus (OLP) is an immune-related disorder affecting 84M people worldwide (10M in EU and USA). OLP is a chronic condition which can ultimately lead to precancerous lesions, while patients suffering from it may struggle daily with painful and/or burning sensations in the oral mucosa, being thus kept from living their normal lives. Since there is no approved cure for OLP, the primary goals of its treatment are the alleviation of symptoms and the minimization of mucosal damage from erosive lesions. Current therapeutic options involve the use of topical corticosteroids (typically Clobetasol). However, the ways of use available in the market show lack of adherence to the mucosa and there is a high chance that the product is spread to other areas (which results in reduced efficacy and potentially causing undesired topical and systemic side effects). Our Danish company AFYX Therapeutics A/S was founded in 2014 with the aim to develop innovative approaches to treat mucosal diseases such as OLP. We have developed our first product incorporating an innovative technology (using an electrospinning process): the RIVELIN®-CLO patch. It’s the first to have been developed exclusively for the treatment of OLP, and its unique properties include self-adherence to the oral tissues (2h of topical drug application); occlusion of the lesion; lower bystander toxicity (Clobetasol is prevented from being spread by saliva) and the correct dosing every time. Clinical Phase IIb trials of the patch are ongoing with clinics and hospitals across EU and US and through this project we aim to guarantee that RIVELIN®-CLO is a success from a technical, commercial and financial perspectives, before launching it to the international markets. Five years after market launch, we expect to gather 7% of the EU and US combined OLP treatment market share, generating €22.6M revenues to our company and increasing our staff to 40 employees and generate new IP to venture new markets with our technology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RIVELIN-CLO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RIVELIN-CLO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More